Top Page
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
(1558)
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) vs. iShares MSCI Hong Kong ETF (EWH)
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Business Overview & Revenue Model
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 3.72B | 6.29B | 3.74B | 913.79M | 2.35B | Gross Profit |
| 2.79B | 4.99B | 2.85B | 483.70M | 2.00B | EBIT |
| 674.47M | 2.35B | 322.72M | -458.11M | 833.69M | EBITDA |
| 1.05B | 2.75B | 691.48M | -206.55M | 950.24M | Net Income Common Stockholders |
| 482.71M | 1.99B | 76.60M | -587.65M | 839.46M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.41B | 1.69B | 1.21B | 1.13B | 2.04B | Total Assets |
| 12.43B | 12.74B | 11.89B | 10.54B | 9.56B | Total Debt |
| 2.23B | 2.61B | 3.82B | 3.19B | 3.01B | Net Debt |
| 831.06M | 934.91M | 2.90B | 2.06B | 965.69M | Total Liabilities |
| 3.92B | 4.81B | 5.82B | 4.52B | 4.46B | Stockholders Equity |
| 8.51B | 7.94B | 5.88B | 5.81B | 4.89B |
| Cash Flow | Free Cash Flow | |||
| 0.00 | 1.08B | 1.13B | -1.02B | 305.33M | Operating Cash Flow |
| 0.00 | 1.67B | 1.70B | -662.51M | 1.30B | Investing Cash Flow |
| 0.00 | 554.57M | -1.12B | -439.11M | -2.09B | Financing Cash Flow |
| 0.00 | -1.48B | -787.03M | 187.48M | 64.63M |
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Technical Analysis
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$12.50B | 23.90 | 5.88% | ― | -42.02% | -76.29% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
| $124.52B | 6.11 | 7.57% | ― | ― | |||
| $10.87B | 46.27 | 6.14% | 1.22% | ― | ― | ||
| $13.30B | 19.73 | 13.20% | 2.55% | ― | ― | ||
| $3.41B | 10.08 | 10.17% | 0.48% | ― | ― | ||
| $4.58B | 13.22 | 14.56% | 4.69% | ― | ― |
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Corporate Events
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced its 2025 Annual General Meeting (AGM) scheduled for May 29, 2025, in Dongguan, Guangdong Province, China. The AGM will address several resolutions, including the approval of the 2024 annual financial reports and the re-appointment of KPMG as the company’s auditor. This meeting is significant for stakeholders as it will determine the company’s financial and operational strategies for the upcoming year.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is undergoing a proposed pre-conditional privatization by Sunshine Lake Pharma Co., Ltd. through a merger by absorption. The merger is contingent upon fulfilling several pre-conditions, including obtaining necessary governmental approvals and listing permissions. As of the latest update, the NDRC approval has been obtained, but other approvals and conditions are still pending. The merger’s completion remains uncertain, and stakeholders are advised to stay informed about further announcements regarding the fulfillment of these conditions.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. reported a significant decline in financial performance for the year ending December 31, 2024, with a 40.84% decrease in revenue and a 75.78% drop in profit attributable to equity shareholders. Despite these challenges, the company has made strides in expanding its product pipeline, particularly in the chronic disease and new drug sectors. The launch of self-developed insulin products and the approval of innovative drugs like Olorigliflozin and Encofosbuvir Tablets mark significant milestones, enhancing the company’s competitive position in the pharmaceutical industry.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. announced the approval and upcoming launch of its Encofosbuvir Tablets, a Class I innovative drug for treating Hepatitis C. This approval marks a significant milestone for the company, enhancing its competitive edge in the hepatitis C treatment market and reinforcing its position as a leader among innovative pharmaceutical companies in China.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has announced a board meeting scheduled for March 28, 2025, to discuss and approve the annual results for the year ending December 31, 2024, and consider the payment of a final dividend. This meeting is significant as it will determine the company’s financial standing and potential shareholder returns, impacting its market position and stakeholder interests.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is undergoing a proposed pre-conditional privatization through a merger by absorption with Sunshine Lake Pharma Co., Ltd. The merger process involves several pre-conditions, including approvals from various regulatory bodies and shareholder consent. As of the latest update, one of the pre-conditions has been fulfilled, and applications and filings have been made to relevant authorities. The company is awaiting further approvals to proceed with the merger, which could impact its market positioning and stakeholder interests.
The recent joint announcement details the progress of the proposed pre-conditional privatization of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. by Sunshine Lake Pharma Co., Ltd. through a merger by absorption. While one of the pre-conditions has been fulfilled, with filings made to the relevant authorities, the merger remains conditional on further approvals and filings, including those from the Stock Exchange and the China Securities Regulatory Commission. Stakeholders are advised that the merger agreement’s effectiveness is still uncertain, pending the fulfillment of these conditions.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has renewed its Sharing Agreement with Sunshine Lake Pharma for 2025, allowing the company to receive a percentage of sales revenue from designated pharmaceutical products in both centralized and non-centralized tender businesses. This agreement extends till the end of 2025 and stipulates that Sunshine Lake Pharma will provide a breakdown of revenues and profits, distributing them to YiChang HEC ChangJiang Pharmaceutical after annual audits. The renewal is based on multiple factors, including profit margins and cost-to-revenue ratios, and aims to continue the benefits derived from the sharing arrangement.